Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines

Blood

Volumn 90, Issue 8, 1997, Pages 3204-3213

  Hill, Geoffrey R ^b   Crawford, James M ^b   Cooke, Kenneth R ^b   Brinson, Yani S ^b   Pan, Luying ^b   Ferrara, James L M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; INFLAMMATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RADIATION INJURY; WHOLE BODY RADIATION;

EID: 0030861750     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.8.3204     Document Type: Article

References (51)

1. Nash A, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden RA, Deeg HJ, Doney K, Martin PJ, Sullivan KM, Sanders J, Witherspoon R: Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transpantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838, 1992
2. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LB, Anasetti C, Beatty P, Bensigner WI, Doney K, Hill RS, McDonald GB, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76:1867, 1990
3. Clift RA, Buckner CD, Thomas WI, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
4. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW: Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 7:193, 1991
5. Lehnert S, Rybka WB, Seemayer TA: Amplification of the graft versus host reaction by partial body irradiation. Transplantation 41:675, 1986
6. Lehnert S, Rybka WB: Amplification of the graft-versus-host reaction by cyclophosphamide: Dependence on timing of drug administration. Bone Marrow Transplant 13:473, 1994
7. Sykes M, Eisenthal A, Sachs DH: Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. J Immunol 140:2903, 1988
8. Truitt RL, Atasoylu AA: Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 77:2515, 1991
9. Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dahlberg S, Ramberg R, Thomas ED: Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anaemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft versus host disease. Blood 67:811, 1986
10. Morse HC, Shen FW, Hammerling U: Genetic nomenclature for loci controlling mouse lymphocyte antigens. Immunogenetics 25:71, 1987
11. Krenger W, Snyder KM, Byon CH, Falzarano G, Ferrara JLM: Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155:585, 1995
12. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Crawford JM, Ferrara JLM: An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 88:3230, 1996
13. Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA: Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol 151:5726, 1993
14. Blazar BR, Taylor PA, Panaskoltsis-Mortari A, Gray GS, Vallera DA: Co-blockade of the LFA1:ICAM and CD28/B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully MHC disparate donor grafts. Blood 83:3815, 1995
15. Fontaine P, Perreault C: Diagnosis of graft-versus-host disease in mice transplanted accross minor histocompatibility barriers. Transplantation 49:1177, 1990
16. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038, 1995
17. Crawford JM: Graft-versus-host disease of the liver, in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft-Versus-Host Disease. New York, NY, Marcel Dekker, 1997, p 315
18. Mowat A: Intestinal graft versus disease, in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft-Versus-Host Disease. New York, NY, Marcel Dekker, 1997, p 337
19. Sykes M: Chimerism and central tolerance. Curr Opin Immunol 8:694, 1996
20. Holler E, Ferrara JLM: Antagonists of inflammatory cytokines: Prophylactic and therapeutic applications, in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft-Versus-Host Disease. New York, NY, Marcel Dekker, 1997, p 667
21. Holler E, Kolb HJ, Moller A, Kempeni J, Lisenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermuller J, Wilmanns W: Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 75:1011, 1990
22. Jacobs CA, Beckmann MP, Mohler K, Maliszewski CR, Fanslow WC, Lynch DC: Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol 34B:123, 1993
23. Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405, 1992
24. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE: Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J Immunol 152:1004, 1994
25. Ghayur T, Seemayer T, Lapp WS: Histologic correlates of immune functional deficits in graft-vs-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-Versus-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Marcel Dekker, 1990, p 109
26. Nestel F, Kichian K, You-Ten K, Desbarats J, Price K, Lapp WS: The role of endotoxin in the pathogenesis of acute graft-versus-host disease, in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft-Versus-Host Disease (ed 2). New York, NY, Marcel Dekker, 1997, p 501
27. Iwamoto KS, McBride WH: Production of 13-hydroxyoctadecadienoic acid and tumor necrosis factor-α by murine peritoneal macrophages in response to irradiation. Radiat Res 139:103, 1994
28. Chiang C, McBride WH: Radiation enhances tumour necrosis factor α production by murine brain cells. Brain Res 566:265, 1991
29. Redlich CA, Gao X, Rockwell S: IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 157:1705, 1996
30. Piguet PF, Grau GE, Allet B, Vassalli PJ: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 166:1280, 1987
31. Wall DA, Sheehan KC: The role of tumor necrosis factor-alpha and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation 57:273, 1994
32. Shalaby MR, Fendly B, Sheehan KC, Schreiber RD, Ammann AJ: Prevention of the graft-vs-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation 47:1057, 1989
33. Holler E, Kolb HJ, Mittermueller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, Kempeni J, Wilmanns W: Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 86:890, 1995
34. Vallera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR: Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 60:1371, 1995
35. Braun YM, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657, 1996
36. Baker MB, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996
37. Wang JH, Redmond HP, Watson RW, Bouchier-Hayes D: Role of lipopolysaccharide and tumor necrosis factor-alpha in induction of hepatocyte necrosis. Am J Physiol 269(2 Pt 1):G297, 1995
38. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB: Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360, 1994
39. Budach W, Hatford A, Gioioso D, Freeman J, Taghian A, Suit HD: Tumours arising in SCID mice share enhanced radiation sensitivity of SCID normal tissues. Cancer Res 52:6292, 1992
40. Girinsky TA, Pallardy M, Comoy E, Benassi T, Roger R, Ganem G, Cosset JM, Socie G, Magdelenat H: Peripheral blood corticotropin-releasing factor, adrenocorticotropic hormone and cytokine (interleukin beta, interleukin 6, tumour necrosis factor alpha) levels after high-and low dose total body irradiation in humans. Radiat Res 139:360, 1994
41. Eissner G, Kohlhuber F, Grell M, Ueffing M, Scheurich P, Hieke A, Multhoff G, Bornkamm GW, Holler E: Critical involvement of transmembrane tumor necrosis factor-α in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood 86:4184, 1995
42. Remick DG: Lung and gut injury induced by tumour necrosis factor. Res Immunol 144:326, 1993
43. van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D: Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 52:401, 1974
44. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, Doney K, Hansen JA, Mason M, Sanders JE, Singer J, Sullivan KM, Witherspoon RP, Thomas ED: Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 308:302, 1983
45. Moller J, Skirhoj P, Hoiby N, Peterson FB: Protection against graft versus Host disease by gut sterilization? Exp Hematol 10:101, 1982
46. van Bekkum DW, Knaan S: Role of bacterial microflora in development of intestinal lesions from graft versus host disease. J Nat Cancer Inst 58:787, 1977
47. Sherman ML, Datta R, Hallahan DE, Weichselbaum RR, Kufe DW: Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J Clin Invest 87:1794, 1991
48. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR: Increased tumor necrosis factor-α mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 86:10104, 1989
49. Castenskiold EC, Kelsey SM, Collins PW, Coldwell RD, Allen PD, Side LE, Makin HL, Goldstone AH, Newland AC: Functional hyperactivity of monocytes after bone marrow transplantation: Possible relevance for the development of post-transplant complications or relapse. Bone Marrow Transplant 15:879, 1995
50. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C: Effect of IgM-enriched intravenous immunoglobulin (Pentaglobulin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 23:540, 1993
51. Haziot A, Rong XY, Sliver J, Goyert SM: Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 154:6529, 1995